Update on cancer vaccines

Current Opinion in Oncology

Volumn 17, Issue 6, 2005, Pages 573-577

  Stevenson, Freda K ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cancer; DNA vaccines; Immunity; Vaccines

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CANCER VACCINE; DNA VACCINE; FREUND ADJUVANT; IMMUNOGLOBULIN; KEYHOLE LIMPET HEMOCYANIN; OLIGONUCLEOTIDE; PEPTIDE DERIVATIVE; PLASMID DNA; TUMOR ANTIGEN; VIRUS VECTOR;

ACTIVE IMMUNIZATION; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CORRELATION ANALYSIS; DENDRITIC CELL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; GENE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOLOGY; MELANOMA; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; REVIEW; TUMOR CELL; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 27644508279     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000181406.60213.c7     Document Type: Review

References (45)

1. Eckhart W. Viruses and human cancer. Sci Prog 1998; 81:315-328.
2. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-1859.
3. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
4. Darnell RB, Posner JB. Observing the invisible: successful tumor immunity in humans. Nat Immunol 2003; 4:201.
5. Maloney DG, Liles TM, Czerwinski DK, etal. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457-2466.
6. Rooney CM, Aguilar LK, Huls MH, et al. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol 2001; 258:221-229.
7. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157:125-140.
8. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18: 798-808.
9. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100:2742-2747.
10. Schilbach K, Kerst G, Walter S, et al. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 2005. The ability of artificial antigen-presenting cells to expand CD8+ T cells from healthy donors is a potentially useful technology. The artificial antigen-presenting cells were coated with anti-CD28 and with major histocompatibility complex class I molecules loaded with the HA-1 nonapeptide. CD8+T cells with cytotoxic activity were induced and could be purified for potential clinical use.
11. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-2357. A combination of lymphodepleting chemotherapy followed by adoptive transfer of tumor-reactive lymphocytes was used to treat patients with refractory metastatic melanoma. High-dose interleukin-2 was also given. Responses (51%) included 3 complete remissions and 15 partial remissions ∼1 year out. Some toxicity and infections were observed.
12. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-519.
13. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005; 16:457-472.
14. Kruger T, Schoor O, Lemmel C, et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2004. The question whether peptides from target intracellular tumor antigens are expressed in a form accessible for CTL attack is important. By the analysis of human leucocyte antigen peptide ligands with mass spectrometry combined with gene expression profiling, several candidate peptides have been detected. This opens the way for the analysis of potential target peptides for personalized vaccines.
15. McCarthy H, Ottensmeier CH, Hamblin TJ, et al. Anti-idiotype vaccines. Br J Haematol 2003; 123:770-781.
16. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5:1171-1177.
17. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99:1517-1526.
18. Stevenson FK, Rice J, Zhu D. Tumor vaccines. Adv Immunol 2004; 82:49-103. This comprehensive review of tumor vaccines aims to sift out the most promising approaches to cancer vaccines. The detailed description of the molecular forms of tumor antigens and the nature of the relevant pathways of immune attack can be used for reference. Tolerance and immune evasion are considered, and the wide range of vaccine strategies to induce effective anticancer immunity is explored.
19. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188:22-32.
20. Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101(Suppl 2):14631-14638. The sensitivity of detection of relevant CTL responses needs to be high, especially because low responses can apparently be important in controlling tumor. In melanoma, a restricted MAGE-3-specific T cell receptor repertoire has been used as a basis for increased sensitivity. By the use of this strategy, a correlation between immune response and tumor regression was observed.
21. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201:241-248. This is part of the detailed analysis of immune responses to defined melanoma antigens carried out by this group in a few patients. An important observation was that the spontaneous antitumor response against nonvaccine antigens, which had become ineffective, could be reawakened by vaccination with another tumor antigen. Both sets of T cells can then contribute to tumor rejection.
22. Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201:249-257. On the same theme of vaccination against melanoma, the group also observed that antivaccine and antitumor T cells were enriched in metastatic deposits. Again, antitumor T cells were at higher levels than antivaccine, but the latter reactivity could have stimulated the antitumor response. The localization of immune reactivity was highlighted and is clearly important.
23. Britten CM, Meyer RG, Kreer T, et al. The use of HLA-A0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002; 259:95-110.
24. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915. This review of the disappointing results of clinical trials of cancer vaccines, largely in melanoma, is from an influential group and sends a pessimistic message. It is therefore important to note that the clinical settings were not optimal and that the vaccine formulations were often poorly immunogenic. There were two robust responses [25,26] pointing out these facts.
25. Mocellin S, Mandruzzato S, Bronte V, et al. Cancer vaccines: pessimism in check. Nat Med 2004, 10:1278-1279; author reply 1279-1280.
26. Timmerman JM, Levy R. Cancer vaccines: pessimism in check. Nat Med 2004, 10:1279; author reply 1279-1280.
27. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996; 93:9730-9735.
28. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-746. The value of stimulating the innate immune response was illustrated, again in a pilot melanoma trial. The addition of a CpG oligonucleotide to a Melan A (MART-1) analogue peptide led to rapid and strong CTL responses in 8 of 8 patients. The control group without CpG showed a much reduced (10 ×) response. Induced CTLs were able to kill target tumor cells. This relatively simple addition to a vaccine formulation seems highly effective.
29. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421:852-856.
30. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-2601. The role of regulatory T cells in modulating immunity against cancer is a focus of interest. It is clear that conventional CD4+ T cell help are required to help induction and maintenance of immunity, and they are critical for breaking tolerance against self antigens; however, this paper shows that if CD4+ T regulatory cells are also present, the outcome is suppression. Successful vaccination has to overcome this T regulatory cell-mediated suppression.
31. Weng WK, Czerwinski D, Timmerman J, et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22:4717-4724. In this study of 136 patients with follicular lymphoma who were vaccinated with idiotypic immunoglobulin protein coupled to KLH, the induction of a humoral response correlated positively with clinical outcome. This is in line with lymphoma models in which anti-idiotypic antibody suppresses tumor. Interestingly, antibody is further implicated by the apparent influence of the FcgIII receptor, known to be involved in antibody-dependent cellular cytotoxicity. Polymorphisms in this receptor are known to predict responses to anti-CD20 antibody therapy, and they also seem to predict idiotypic vaccine efficacy.
32. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004; 172:2532-2538. This is a review of the clinical trials of dendritic cell vaccines as applied to advanced prostate cancer. Immunologie responses and clinical effects are assessed. 33 Gilboa E, Vieweg J. Cancer immune-therapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199:251-263. This laboratory has pioneered the use of RNA-transfected dendritic cells as cancer vaccines. The review summarizes promising clinical data using this approach in two trials. Vaccination with mRNA-loaded dendritic cells encoding prostate-specific antigen induces T cell responses with some clinical benefit.
33. Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337:567-572.
34. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11:3353-3362.
35. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18:927-974.
36. Spies B, Hochrein H, Vabulas M, et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003; 171:5908-5912.
37. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005; 174:727-734. An understanding of the link between innate and adaptive immunity is critical for vaccine development. The issue of the role of plasmacytoid dendritic cells is also important in relation to DNA vaccines wherein CpG stimulation is involved. The study points to a reciprocal activating interaction between natural killer cells and dendritic cells, either plasmacytoid or myeloid dendritic cells, which is part of this link.
38. Dupuis M, Denis-Mize K, Woo C, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165:2850-2858.
39. Otten G, Schaefer M, Doe B, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004; 22:2489-2493.
40. Buchan S, Gronevik E, Mathiesen I, et al. Electroporation as a 'prime/boost' strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174:6292-6298. The performance of DNA vaccines in large animals can be dramatically improved by a 'prime/boost' strategy. Commonly the boost is delivered by a viral vector. To avoid the problems of viral vectors, a physical method, electroporation, can be used at the stage of boosting. The key is likely to be to increase antigen expression by amplification of transfection, and attraction of dendritic cells to the injection site.
41. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-1244.
42. Zhu D, Stevenson FK. DNA gene fusion vaccines against cancer. Curr Opin Mol Ther 2002; 4:41-48.
43. Stevenson FK, Ottensmeier CH, Johnson P, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci USA 2004; 101(Suppl 2):14646-14652.
44. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4:1281-1286.
45. Rice J, Buchan S, Dewchand H, et al. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. J Immunol 2004; 173:4492-4499. Breaking peripheral tolerance is desirable for vaccinating against self tumor antigens. For DNA vaccines, one way is to add microbial genes to provide T cell help from the nontolerized repertoire. A simple fusion between the tumor antigen gene and a microbial gene can overcome toleragenic pressure and induce immunity even in a highly regulated immune response.